Prophylactic Application of Donor-derived TCM After Allogeneic HSCT

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

May 31, 2021

Study Completion Date

May 31, 2021

Conditions
Leukemia, Myeloid, AcuteMyelodysplastic Syndromes
Interventions
BIOLOGICAL

TCM allogeneic humane central memory T cells, cryopreserved

Experimental: TCM allogeneic humane central memory T cells, cryopreserved Solution for injection (intravenous use) up to 65\*10\^4 TCM /kg body weight patient will receive investigational product 3 times (Day 30, Day 60, Day 90 after alloHSCT)

Trial Locations (1)

Unknown

University Hospital Wuerzburg - Department of Medicine II, Würzburg

All Listed Sponsors
lead

Wuerzburg University Hospital

OTHER

NCT02758223 - Prophylactic Application of Donor-derived TCM After Allogeneic HSCT | Biotech Hunter | Biotech Hunter